MedTrace Logo

Pyruvate Kinase Isoform M2 (PKM2) as a Possible Biomarker for Cancer

NCT01130584 · Status: COMPLETED · Type: OBSERVATIONAL

Last updated 2013-12-11

No results posted yet for this study

Summary

The purpose of this study is to determine if pyruvate kinase M2 (PKM2) can be used as a biomarker in cancer.

Pyruvate kinase M2 is more elevated in malignant pleural fluid than in plasma, and may be a useful biomarker to distinguish between malignant and non-malignant causes of pleural effusion. In addition, pyruvate kinase M2 has also been found to be elevated in saliva in cancer patients compared to controls. Measuring pyruvate kinase M2 in saliva may be used to diagnose cancer or monitor the treatment progress of cancer.

Conditions

Interventions

OTHER

Pyruvate kinase isoform M2

Sponsors & Collaborators

  • National University Hospital, Singapore

    lead OTHER

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2013-04-30
Completion
2013-04-30

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01130584 on ClinicalTrials.gov